{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:00:59Z","timestamp":1770814859285,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Non\u2010steroidal anti\u2010inflammatory drugs (NSAIDs) are well known for their most frequent side effects (digestive, renal and metabolic disorders) but are lesser known for other effects, such as coagulation disturbances. In this issue, we report the case of a 58\u2010year\u2010old woman who ingested 26\u00a0g of naproxen in a suicidal attempt and developed cardiovascular shock, hypocoagulability and thrombopenia. Her outcome was positive (extubation 3\u00a0days after admission [D3], correction of haemostatic disruptions on D5 and of thrombopenia on D6). Naproxen plasma concentration was at a toxic concentration of 1320\u00a0mg\/L at 6\u00a0hours after drug ingestion. Only few cases of hypocoagulopathy are reported with the NSAIDs, and this is the first case that can be attributed to naproxen. A possible explanation of this phenomenon following naproxen ingestion is an inhibition of thromboxane A2, usually attributed to NSAIDs, combined with an inhibition of activation of downstream the cascade.<\/jats:p>","DOI":"10.1111\/bcpt.13365","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T18:44:24Z","timestamp":1574189064000},"page":"458-463","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Severe poisoning with naproxen causing coagulopathy"],"prefix":"10.1111","volume":"126","author":[{"given":"B\u00e9n\u00e9dicte","family":"Leli\u00e8vre","sequence":"first","affiliation":[{"name":"Pharmacology and Toxicology Laboratory\u2010Pharmacovigilance Center CHU Angers France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Drouillard","sequence":"additional","affiliation":[{"name":"Army Training Hospital Brest France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chlo\u00e9","family":"Thill","sequence":"additional","affiliation":[{"name":"Army Training Hospital Brest France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00ebl","family":"Le Roux","sequence":"additional","affiliation":[{"name":"Poison Control Center CHU Angers France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chlo\u00e9","family":"Bruneau","sequence":"additional","affiliation":[{"name":"Poison Control Center CHU Angers France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Mah\u00e9","sequence":"additional","affiliation":[{"name":"Pharmacology Department CHU Nantes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Deguigne","sequence":"additional","affiliation":[{"name":"Poison Control Center CHU Angers France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Boels","sequence":"additional","affiliation":[{"name":"Poison Control Center CHU Angers France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,12,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650802559632"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199005040-00003"},{"key":"e_1_2_8_4_1","unstructured":"Resume des caracteristiques du produit. Naproxene. Document consulted on the sitehttp:\/\/www.agence-prd.ansm.sante.fr(2018 November the 11th)."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/37.7.1210"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.07.005"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2013016"},{"key":"e_1_2_8_8_1","first-page":"448","article-title":"Therapeutic and toxic blood concentrations of more than 800 drugs and others xenobiotics","volume":"58","author":"Schulz M","year":"2003","journal-title":"Pharmazie"},{"key":"e_1_2_8_9_1","volume-title":"Disposition of Toxic Drugs and Chemicals in Man","author":"Baselt RC","year":"2011"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563659509000469"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.50.3.297"},{"issue":"8","key":"e_1_2_8_12_1","first-page":"1","article-title":"Citalopram inhibits platelet function independent of SERT\u2010mediated 5\u2010HT transport","volume":"3493","author":"Roweth HG","year":"2018","journal-title":"Sci Rep"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199732040-00002"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1974153261"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1976203269"},{"key":"e_1_2_8_16_1","unstructured":"Fiche Micromedex\u00ae sur le naproxene. Document available athttp:\/\/www.Micromedexsolutions.com"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mej.0000224428.51623.b2"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-014-0396-1"},{"key":"e_1_2_8_19_1","unstructured":"Summary product characteristic of APRANAX\u00ae750mg. Available athttp:\/\/base-donneespublique.medicaments.gouv.fr\/"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002808301700713"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1995.tb04050.x"},{"key":"e_1_2_8_22_1","first-page":"107","article-title":"Ibuprofen toxicity. Review of adverse reaction and overdose","volume":"12","author":"Halpern SM","year":"1993","journal-title":"Adverse Drug React Toxicol Rev"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra066469"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13365","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcpt.13365","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T21:40:50Z","timestamp":1694036450000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.13365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1111\/bcpt.13365"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.13365","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,5]]},"assertion":[{"value":"2019-10-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}